Chong Kun Dang Pharmaceutical Corp
KRX:185750
Chong Kun Dang Pharmaceutical Corp
KRX:185750
Price:
93 300
KRW
0.65%
Market Cap:
1.2T
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Chong Kun Dang Pharmaceutical Corp
93300
+600 (+0.65%)
| 52 Week Range |
86 000
133 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Chong Kun Dang Pharmaceutical Corp
Balance Sheet
Balance Sheet Decomposition
Chong Kun Dang Pharmaceutical Corp
Chong Kun Dang Pharmaceutical Corp
| Current Assets | 984B |
| Cash & Short-Term Investments | 333.7B |
| Receivables | 297.2B |
| Other Current Assets | 353.2B |
| Non-Current Assets | 477.5B |
| Long-Term Investments | 68.8B |
| PP&E | 318.5B |
| Intangibles | 69.4B |
| Other Non-Current Assets | 20.8B |
| Current Liabilities | 387.3B |
| Accounts Payable | 196.4B |
| Accrued Liabilities | 16.4B |
| Short-Term Debt | 91.1B |
| Other Current Liabilities | 83.3B |
| Non-Current Liabilities | 181.1B |
| Long-Term Debt | 119.2B |
| Other Non-Current Liabilities | 61.9B |
Balance Sheet
Chong Kun Dang Pharmaceutical Corp
Chong Kun Dang Pharmaceutical Corp
Currency: KRW
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
48 771
|
12 853
|
21 720
|
45 472
|
45 948
|
76 922
|
123 659
|
131 813
|
117 417
|
218 834
|
|
| Cash |
810
|
776
|
678
|
281
|
656
|
256
|
218
|
238
|
268
|
256
|
|
| Cash Equivalents |
47 961
|
12 077
|
21 042
|
45 191
|
45 292
|
76 666
|
123 441
|
131 575
|
117 149
|
218 578
|
|
| Short-Term Investments |
2 580
|
0
|
0
|
0
|
0
|
15 451
|
38 196
|
55 520
|
38 444
|
145 419
|
|
| Total Receivables |
161 656
|
175 932
|
209 634
|
210 298
|
208 288
|
198 007
|
219 514
|
228 295
|
279 749
|
310 140
|
|
| Accounts Receivables |
152 586
|
165 844
|
196 706
|
192 766
|
191 563
|
174 708
|
183 722
|
203 684
|
248 893
|
270 702
|
|
| Other Receivables |
9 070
|
10 088
|
12 928
|
17 532
|
16 725
|
23 299
|
35 792
|
24 611
|
30 855
|
39 438
|
|
| Inventory |
75 236
|
89 983
|
98 261
|
104 339
|
127 591
|
148 454
|
185 565
|
224 723
|
270 081
|
261 432
|
|
| Other Current Assets |
10 191
|
9 597
|
9 142
|
6 796
|
8 503
|
32 301
|
33 179
|
26 797
|
7 924
|
10 747
|
|
| Total Current Assets |
298 435
|
288 365
|
338 757
|
366 904
|
390 331
|
471 135
|
600 114
|
667 147
|
713 615
|
946 572
|
|
| PP&E Net |
215 240
|
228 027
|
244 676
|
252 377
|
254 109
|
263 086
|
274 650
|
298 910
|
310 697
|
319 787
|
|
| PP&E Gross |
215 240
|
228 027
|
244 676
|
252 377
|
254 109
|
263 086
|
274 650
|
298 910
|
310 697
|
319 787
|
|
| Accumulated Depreciation |
136 881
|
155 247
|
175 040
|
194 383
|
213 055
|
229 597
|
246 592
|
267 826
|
296 793
|
322 999
|
|
| Intangible Assets |
16 074
|
15 844
|
14 858
|
14 334
|
15 376
|
15 915
|
19 033
|
20 806
|
26 953
|
52 527
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
2 198
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
41 244
|
40 056
|
40 628
|
38 983
|
46 206
|
48 379
|
49 753
|
54 551
|
65 100
|
67 172
|
|
| Other Long-Term Assets |
2 761
|
3 995
|
2 779
|
4 608
|
3 275
|
2 837
|
2 783
|
5 287
|
8 517
|
16 371
|
|
| Total Assets |
573 754
N/A
|
576 287
+0%
|
641 699
+11%
|
677 205
+6%
|
711 495
+5%
|
801 352
+13%
|
946 333
+18%
|
1 046 700
+11%
|
1 124 883
+7%
|
1 402 428
+25%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
40 051
|
49 529
|
71 204
|
71 181
|
68 592
|
101 969
|
144 120
|
129 327
|
145 436
|
183 939
|
|
| Accrued Liabilities |
14 121
|
17 017
|
18 874
|
22 047
|
20 226
|
19 684
|
13 812
|
15 818
|
19 876
|
27 465
|
|
| Short-Term Debt |
28 600
|
28 600
|
53 967
|
41 100
|
58 100
|
52 312
|
73 049
|
74 656
|
96 270
|
90 959
|
|
| Current Portion of Long-Term Debt |
52 000
|
25 367
|
30 600
|
40 000
|
478
|
39 901
|
5 583
|
27 435
|
28 176
|
93 808
|
|
| Other Current Liabilities |
26 546
|
30 929
|
36 797
|
49 719
|
57 114
|
63 202
|
84 057
|
72 993
|
84 456
|
115 294
|
|
| Total Current Liabilities |
161 317
|
151 443
|
211 442
|
224 048
|
204 509
|
277 069
|
320 621
|
320 230
|
374 213
|
511 466
|
|
| Long-Term Debt |
43 967
|
70 600
|
40 000
|
21 358
|
45 892
|
25 845
|
57 509
|
134 962
|
111 293
|
34 997
|
|
| Deferred Income Tax |
5 886
|
2 968
|
997
|
2 277
|
711
|
924
|
1 631
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
1 580
|
2 174
|
1 433
|
166
|
200
|
1 104
|
59
|
|
| Other Liabilities |
31 136
|
36 715
|
35 009
|
26 227
|
29 483
|
22 561
|
14 979
|
25 698
|
18 088
|
40 331
|
|
| Total Liabilities |
242 306
N/A
|
261 726
+8%
|
287 448
+10%
|
275 490
-4%
|
282 770
+3%
|
327 832
+16%
|
394 906
+20%
|
480 690
+22%
|
502 490
+5%
|
586 734
+17%
|
|
| Equity | |||||||||||
| Common Stock |
23 523
|
23 523
|
23 523
|
23 523
|
24 698
|
25 926
|
27 214
|
28 565
|
29 970
|
31 421
|
|
| Retained Earnings |
34 569
|
19 533
|
58 889
|
106 031
|
142 551
|
189 029
|
272 194
|
302 107
|
376 371
|
577 002
|
|
| Additional Paid In Capital |
271 383
|
271 383
|
271 383
|
271 383
|
270 207
|
268 980
|
267 691
|
266 340
|
264 935
|
263 484
|
|
| Unrealized Security Profit/Loss |
2 357
|
506
|
840
|
1 531
|
865
|
2 491
|
4 914
|
6 599
|
6 891
|
7 847
|
|
| Treasury Stock |
384
|
384
|
384
|
384
|
7 334
|
7 777
|
10 584
|
22 435
|
34 666
|
48 143
|
|
| Other Equity |
0
|
0
|
0
|
369
|
532
|
147
|
174
|
1 967
|
7 326
|
224
|
|
| Total Equity |
331 448
N/A
|
314 561
-5%
|
354 250
+13%
|
401 715
+13%
|
428 725
+7%
|
473 520
+10%
|
551 427
+16%
|
566 010
+3%
|
622 393
+10%
|
815 694
+31%
|
|
| Total Liabilities & Equity |
573 754
N/A
|
576 287
+0%
|
641 699
+11%
|
677 205
+6%
|
711 495
+5%
|
801 352
+13%
|
946 333
+18%
|
1 046 700
+11%
|
1 124 883
+7%
|
1 402 428
+25%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
13
|
13
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
